A research team led by a Medical University of South Carolina (MUSC) investigator reports in the May 6 issue of the New England Journal of Medicine that a four-month treatment regimen using rifapentine is effective for treating TB. Shortening the treatment duration is an important step toward increased patient adherence. Read here
TB-PRACTECAL, a clinical trial led by Médecins Sans Frontières (MSF), has found that a new, all-oral, six-month treatment regimen is safer and more effective at treating rifampicin-resistant tuberculo
Using cutting-edge genomic sequencing techniques, researchers at the University of Oxford have identified almost all the genomic variation that gives people resistance to 13 of the most common tubercu
Hundreds of patient volunteers from four continents have enrolled in a trial that aims to find safer, shorter, and effective treatments for multidrug-resistant tuberculosis (MDR-TB), an airborne, infe